Compare OGN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | ANAB |
|---|---|---|
| Founded | 1923 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 2015 |
| Metric | OGN | ANAB |
|---|---|---|
| Price | $13.72 | $49.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $11.25 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 1.9M | 486.6K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $6,216,000,000.00 | $234,603,000.00 |
| Revenue This Year | N/A | $17.97 |
| Revenue Next Year | $2.51 | $36.88 |
| P/E Ratio | $14.43 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $5.69 | $30.27 |
| 52 Week High | $13.79 | $73.30 |
| Indicator | OGN | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 31.61 |
| Support Level | $13.46 | $43.75 |
| Resistance Level | $13.77 | $51.67 |
| Average True Range (ATR) | 0.04 | 2.24 |
| MACD | -0.00 | -0.45 |
| Stochastic Oscillator | 59.09 | 18.66 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).